#achieve-3

1 story

Clinical Trials March 27, 2026 · View digest

Orforglipron Outperforms Oral Semaglutide in Phase 3 ACHIEVE-3 Trial

Eli Lilly's oral orforglipron demonstrated superior HbA1c reduction and weight loss vs oral semaglutide in Phase 3, strengthening the case ahead of an April FDA decision.